Biohaven Pharmaceuticals
3 known investors
Biohaven is a biopharmaceutical company focused on discovering and developing treatments in immunology, obesity, neuroscience, and oncology, including approved migraine medications. The company advances therapeutic programs for diseases with significant unmet medical needs.
BiotechHealthtechMedical Devices
Investors · 3
In the news
- Biohaven reduces scope of R&D cutbacks as pipeline progressesfiercebiotech.com · 2026
- RBC Capital raises Biohaven Pharma stock price target on model tweaks By Investing.cominvesting.com · 2026
- BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Regionprnewswire.com · 2020